18.01.2017 21:11:00
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Rad Laboratories, Inc. - BIO
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company") (NYSE: BIO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Bio-Rad and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On May 4, 2010, Bio-Rad disclosed that it had self-reported to the U.S. Securities and Exchange Commission and the U.S. Department of Justice after an internal review identified certain practices that violated the Foreign Corrupt Practices Act of 1977. On this news, the Company's stock fell $8.16, or 7.29%, to close at $103.65 on May 5, 2010. On November 3, 2014, Bio-Rad agreed to pay $55 million to settle allegations by U.S. authorities that the Company's subsidiaries had paid bribes to foreign officials in Russia, Thailand and Vietnam and falsified records to mask these bribes as legitimate expenses. On this news, the Company's stock fell $1.61, or $1.41%, to close at $111.80 on November 4, 2014.
On May 27, 2015, Bio-Rad's former General Counsel Sanford Wadler filed a lawsuit alleging that he was fired in 2013 after raising concerns to the Company's audit committee about bribery practices in China and for refusing to turn a blind eye to corruption. On this news, the Company's stock fell $1.63, or $1.13%, to close at $142.36 on May 28, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bio-rad-laboratories-inc--bio-300393007.html
SOURCE Pomerantz LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Rad Laboratories Inc.mehr Nachrichten
29.10.24 |
Ausblick: Bio-Rad Laboratories legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
15.10.24 |
Erste Schätzungen: Bio-Rad Laboratories zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
20.09.24 |
S&P 500 aktuell: Das macht der S&P 500 am Mittag (finanzen.at) | |
16.09.24 |
S&P 500-Papier Bio-Rad Laboratories-Aktie: So viel Gewinn hätte ein Bio-Rad Laboratories-Investment von vor 10 Jahren abgeworfen (finanzen.at) | |
09.09.24 |
S&P 500-Titel Bio-Rad Laboratories-Aktie: So viel Verlust hätte ein Investment in Bio-Rad Laboratories von vor 5 Jahren eingebracht (finanzen.at) | |
02.09.24 |
S&P 500-Papier Bio-Rad Laboratories-Aktie: So viel Verlust hätte eine Bio-Rad Laboratories-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
28.08.24 |
Angespannte Stimmung in New York: S&P 500 schwächelt zum Handelsende (finanzen.at) | |
28.08.24 |
Börse New York: S&P 500 am Nachmittag mit Abgaben (finanzen.at) |
Analysen zu Bio-Rad Laboratories Inc.mehr Analysen
Aktien in diesem Artikel
Bio-Rad Laboratories Inc. | 331,10 | -0,51% |